Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (7724)	11/13/1998 11:04:00 AM
From: Arthur Radley	Respond to of 17367

Go to the news here on SI and you will find the earnings release and discussion of XOMA trials.

To: Robert K. who wrote (7724)	11/13/1998 12:53:00 PM
From: Pseudo Biologist	Respond to of 17367

This may be of interest: ncbi.nlm.nih.gov Proc Natl Acad Sci U S A 1998 Nov 10;95(23):13875-13880 Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Schimke J, Mathison J, Morgiewicz J, Ulevitch RJ And you may be aware that ICOS is developing an anti-CD14 antibody for sepsis-like conditions. As they say, "competition and validation." PB